Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of combination of natural immune agonist and brain homeostasis regulatory protein in treating Alzheimer's disease

A technology of natural immunity and protein regulation, applied in the field of biomedicine, can solve the problem that the pathological process of TREM2AD is not very clear

Pending Publication Date: 2020-02-07
LIAOCHENG CITY ORIENT BIOMEDICAL TECH CO LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, how TREM2 participates in and affects the pathological process of AD is still not very clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of natural immune agonist and brain homeostasis regulatory protein in treating Alzheimer's disease
  • Application of combination of natural immune agonist and brain homeostasis regulatory protein in treating Alzheimer's disease
  • Application of combination of natural immune agonist and brain homeostasis regulatory protein in treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: Preparation of STING agonist

[0025] Preparation of cGAMP: cGAMP (cyclized-GMP-AMP) was catalyzed and synthesized by cyclized cGMP-AMP dinucleotide synthetase (cGAS) according to the literature method under activation conditions after binding to DNA. The purity is above 98%. (Pingwei Li, et al., Immunity, 2013, 39(6), 1019-1031.). Thio-cGAMP, c-di-AMP, thio-c-di-AMP, c-di-GMP were purchased from sigma company.

Embodiment 2

[0026] Example 2: Brain Homeostasis Regulation Protein Zn 7 Preparation of MT3gH625

[0027] All biochemical reagents and kits were purchased from Sigama or Invitrogen unless otherwise specified. Zn 7 The preparation of MT3gH625 was carried out according to the literature method. (Wei Xu, Qiming Xu, Hao Cheng, Xiangshi Tan, Scientific reports, 2017, 7(1), 13763.)

[0028] Zn 7 Determination of metal content in MT3gH625

[0029] Take a certain amount of recombined fusion protein Zn 7 MT3gH625 was nitrified overnight at 65°C with a small amount of concentrated nitric acid, diluted 10 times, and the content of metal Zn was measured on an inductively coupled plasma optical emission spectrometer (ICP-OES). The results show that each mole of Zn after recombination 7 The MT3gH625 fusion protein contained 7±0.2 moles of Zn.

[0030] Zn 7 Removal of endotoxin in MT3gH625

[0031] Zn 7 MT3gH625 first uses ultrafiltration membrane to intercept aggregated endotoxin (LPS), and t...

Embodiment 3

[0032] Example 3: Alzheimer's disease mouse model and STING agonist combined with Zn 7 MT3gH625 drug treatment APP / PS1 transgenic mice were purchased from Beijing Zhongke Zesheng Biotechnology Co., Ltd., 4 months old, weighing 24-26g. Test drug name: STING agonist, STING agonist combined with Zn 7 MT3gH625. Properties: white powder. Vehicle: normal saline. Preparation method: Prepare the solution with the required concentration with physiological saline solution before use. The dosage is: 10mg / kg. Administration method: intraperitoneal injection; administration frequency: once a day for 60 consecutive days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Maximum tolerated doseaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of a combination of natural immune agonist and brain homeostasis regulatory protein in treating Alzheimer's disease. The brain homeostasis balance regulatory protein can pass through a blood brain barrier, so that homeostasis balance of brain metal ions is effectively regulated and controlled, homeostasis balance of active oxygen species is effectively inhibited, and toxic senile plaques are effectively reduced. The natural immune agonist can effectively regulate brain immune cell functions and reduce pathological features such as chronic brain inflammation. The combination of the brain homeostasis regulatory protein and the natural immune agonist can significantly improve the nerve cell morphology of hippocampus, inhibit nerve cell apoptosis, eliminate toxic amyloid deposition, improve the learning and memory ability of model mice, and prevent the development of Alzheimer's disease. Therefore, the combination of the brain homeostasis regulatory protein and the natural immune agonist has a wide application prospect in the aspect of treating Alzheimer's disease.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of a natural immune regulator combined with a brain homeostasis regulatory protein in the treatment of Alzheimer's disease. The use of brain homeostasis regulatory proteins combined with natural immune regulators can significantly improve the morphology of neurons in the hippocampus and inhibit the apoptosis of neurons, improve the learning and memory ability of the brain, inhibit amyloid deposition and chronic inflammation of the brain, and prevent the development of Alzheimer's disease. Background technique [0002] Alzheimer's Disease (AD), commonly known as senile dementia, has become one of the most serious diseases in the world. There are few anti-Alzheimer's disease drugs approved by the US FDA and China CFDA, and the drugs treat the symptoms but not the root cause. The curative effect is not significant. Most of the global anti-Alzheimer's ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61P25/28A61P25/16A61P25/02A61P21/00A61P9/14A61P25/14A61P9/10A61P21/02A61P21/04A61K31/7084
CPCA61K38/16A61K31/7084A61P25/28A61P25/16A61P25/02A61P21/00A61P9/14A61P25/14A61P9/10A61P21/02A61P21/04
Inventor 不公告发明人
Owner LIAOCHENG CITY ORIENT BIOMEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com